FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2522966114> ?p ?o ?g. }

• W2522966114 endingPage "1160" @default.
• W2522966114 startingPage "1152" @default.
• W2522966114 abstract "KAF156 belongs to a new class of antimalarial agents (imidazolopiperazines), with activity against asexual and sexual blood stages and the preerythrocytic liver stages of malarial parasites.We conducted a phase 2, open-label, two-part study at five centers in Thailand and Vietnam to assess the antimalarial efficacy, safety, and pharmacokinetic profile of KAF156 in adults with acute Plasmodium vivax or P. falciparum malaria. Assessment of parasite clearance rates in cohorts of patients with vivax or falciparum malaria who were treated with multiple doses (400 mg once daily for 3 days) was followed by assessment of the cure rate at 28 days in a separate cohort of patients with falciparum malaria who received a single dose (800 mg).Median parasite clearance times were 45 hours (interquartile range, 42 to 48) in 10 patients with falciparum malaria and 24 hours (interquartile range, 20 to 30) in 10 patients with vivax malaria after treatment with the multiple-dose regimen and 49 hours (interquartile range, 42 to 54) in 21 patients with falciparum malaria after treatment with the single dose. Among the 21 patients who received the single dose and were followed for 28 days, 1 had reinfection and 7 had recrudescent infections (cure rate, 67%; 95% credible interval, 46 to 84). The mean (±SD) KAF156 terminal elimination half-life was 44.1±8.9 hours. There were no serious adverse events in this small study. The most common adverse events included sinus bradycardia, thrombocytopenia, hypokalemia, anemia, and hyperbilirubinemia. Vomiting of grade 2 or higher occurred in 2 patients, 1 of whom discontinued treatment because of repeated vomiting after receiving the single 800-mg dose. More adverse events were reported in the single-dose cohort, which had longer follow-up, than in the multiple-dose cohorts.KAF156 showed antimalarial activity without evident safety concerns in a small number of adults with uncomplicated P. vivax or P. falciparum malaria. (Funded by Novartis and others; ClinicalTrials.gov number, NCT01753323 .)." @default.
• W2522966114 created "2016-09-30" @default.
• W2522966114 creator A5007007103 @default.
• W2522966114 creator A5012856970 @default.
• W2522966114 creator A5014977844 @default.
• W2522966114 creator A5024446909 @default.
• W2522966114 creator A5028566750 @default.
• W2522966114 creator A5029133026 @default.
• W2522966114 creator A5030133068 @default.
• W2522966114 creator A5031555005 @default.
• W2522966114 creator A5032292453 @default.
• W2522966114 creator A5039600726 @default.
• W2522966114 creator A5046978081 @default.
• W2522966114 creator A5047833835 @default.
• W2522966114 creator A5049128013 @default.
• W2522966114 creator A5051640299 @default.
• W2522966114 creator A5059765665 @default.
• W2522966114 creator A5068058975 @default.
• W2522966114 creator A5069712725 @default.
• W2522966114 creator A5069990013 @default.
• W2522966114 creator A5084217335 @default.
• W2522966114 creator A5091745895 @default.
• W2522966114 date "2016-09-22" @default.
• W2522966114 modified "2023-10-10" @default.
• W2522966114 title "Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria" @default.
• W2522966114 cites W2013955436 @default.
• W2522966114 cites W2027634352 @default.
• W2522966114 cites W2033931346 @default.
• W2522966114 cites W2040095486 @default.
• W2522966114 cites W2050515661 @default.
• W2522966114 cites W2087956351 @default.
• W2522966114 cites W2102395543 @default.
• W2522966114 cites W2124634096 @default.
• W2522966114 cites W2135797423 @default.
• W2522966114 cites W2136730510 @default.
• W2522966114 cites W2143048218 @default.
• W2522966114 cites W2148068300 @default.
• W2522966114 cites W2161311583 @default.
• W2522966114 cites W2169329132 @default.
• W2522966114 cites W2171102256 @default.
• W2522966114 cites W2411807976 @default.
• W2522966114 cites W4242588288 @default.
• W2522966114 doi "https://doi.org/10.1056/nejmoa1602250" @default.
• W2522966114 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5142602" @default.
• W2522966114 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27653565" @default.
• W2522966114 hasPublicationYear "2016" @default.
• W2522966114 type Work @default.
• W2522966114 sameAs 2522966114 @default.
• W2522966114 citedByCount "86" @default.
• W2522966114 countsByYear W25229661142016 @default.
• W2522966114 countsByYear W25229661142017 @default.
• W2522966114 countsByYear W25229661142018 @default.
• W2522966114 countsByYear W25229661142019 @default.
• W2522966114 countsByYear W25229661142020 @default.
• W2522966114 countsByYear W25229661142021 @default.
• W2522966114 countsByYear W25229661142022 @default.
• W2522966114 countsByYear W25229661142023 @default.
• W2522966114 crossrefType "journal-article" @default.
• W2522966114 hasAuthorship W2522966114A5007007103 @default.
• W2522966114 hasAuthorship W2522966114A5012856970 @default.
• W2522966114 hasAuthorship W2522966114A5014977844 @default.
• W2522966114 hasAuthorship W2522966114A5024446909 @default.
• W2522966114 hasAuthorship W2522966114A5028566750 @default.
• W2522966114 hasAuthorship W2522966114A5029133026 @default.
• W2522966114 hasAuthorship W2522966114A5030133068 @default.
• W2522966114 hasAuthorship W2522966114A5031555005 @default.
• W2522966114 hasAuthorship W2522966114A5032292453 @default.
• W2522966114 hasAuthorship W2522966114A5039600726 @default.
• W2522966114 hasAuthorship W2522966114A5046978081 @default.
• W2522966114 hasAuthorship W2522966114A5047833835 @default.
• W2522966114 hasAuthorship W2522966114A5049128013 @default.
• W2522966114 hasAuthorship W2522966114A5051640299 @default.
• W2522966114 hasAuthorship W2522966114A5059765665 @default.
• W2522966114 hasAuthorship W2522966114A5068058975 @default.
• W2522966114 hasAuthorship W2522966114A5069712725 @default.
• W2522966114 hasAuthorship W2522966114A5069990013 @default.
• W2522966114 hasAuthorship W2522966114A5084217335 @default.
• W2522966114 hasAuthorship W2522966114A5091745895 @default.
• W2522966114 hasBestOaLocation W25229661141 @default.
• W2522966114 hasConcept C119060515 @default.
• W2522966114 hasConcept C126322002 @default.
• W2522966114 hasConcept C197934379 @default.
• W2522966114 hasConcept C203014093 @default.
• W2522966114 hasConcept C2775867548 @default.
• W2522966114 hasConcept C2776793103 @default.
• W2522966114 hasConcept C2777425658 @default.
• W2522966114 hasConcept C2778048844 @default.
• W2522966114 hasConcept C2778248108 @default.
• W2522966114 hasConcept C2778371730 @default.
• W2522966114 hasConcept C2779997623 @default.
• W2522966114 hasConcept C2781413609 @default.
• W2522966114 hasConcept C71924100 @default.
• W2522966114 hasConcept C90924648 @default.
• W2522966114 hasConceptScore W2522966114C119060515 @default.
• W2522966114 hasConceptScore W2522966114C126322002 @default.
• W2522966114 hasConceptScore W2522966114C197934379 @default.
• W2522966114 hasConceptScore W2522966114C203014093 @default.
• W2522966114 hasConceptScore W2522966114C2775867548 @default.

• next